From August 9 to 11, Beijing hosted a major medical event – the 30th China International Medical Instrument and Equipment Exhibition & Technical Exchange (China-Hospeq 2024). At this event, AccuMedical showcased its innovative product, the Lattice® Flow Diverter, showcasing the latest breakthroughs in neurointervention.
A Feast of Technology
China-Hospeq 2024 was more than an exhibition; it was a platform for global medical experts to exchange ideas and share experiences. The event was hosted by the International Exchange and Cooperation Center of the National Health Commission, with over 200 high-quality enterprises from more than 10 countries and regions, including China, Germany, the United States, the Netherlands, and Sweden. These companies displayed products, technologies, and the latest solutions to address the health needs of various countries. Participants discussed ways to optimize the global medical trade and investment environment, promote deeper cooperation between Central Asia and China, and support regional health and well-being.
At this international event, AccuMedical, as a representative in the field of neurointervention, attracted the attention of many domestic and international scholars and experts with its innovative Lattice® Flow Diverter technology.
Intracranial aneurysms, often referred to as "ticking time bombs" in the brain, have posed significant challenges for surgeons and patients due to the complexity of traditional treatment procedures and slow post-operative recovery over the past decades. The Lattice® Flow Diverter provides a new solution to this problem. For the first time, it extends the indications for flow diverters to include the treatment of medium and small vertebral artery aneurysms, addressing a critical gap in clinical needs.
The innovative mechanical balloon system equipped on Lattice effectively addresses issues such as stent kinking and opening during surgery, ensuring precise positioning and smooth deployment. Additionally, the application of the MIROR surface modification technology resolves complications thay may arise from metal oxides on the surface of woven stents, significantly enhancing surgical safety.
Bringing Chinese Innovation to the World
Clinical data shows that Lattice® Flow Diverter achieves a high aneurysm occlusion rate of 91.4% at 12 months post-operation, with an in-stent restenosis rate of only 0.8% at 12 months, which demonstrates Lattice’s superior surgical safety and favorable prognosis. Its unique design not only reduces surgical complexity but also improves the accessibility of intracranial aneurysm treatment.
AccuMedical has not only made breakthroughs with Lattice® but also offers a product line that covers interventional devices and access devices for the treatment of hemorrhagic and ischemic strokes. To date, the company has filed 118 patent applications, with 63 granted, and seven products have been approved and entered the commercialization phase.
China-Hospeq 2024 provided a global platform for domestic medical enterprises like AccuMedical. With frequent appearances on international medical exchange platforms, AccuMedical, as a new force in China’s neurointervention field, is injecting new vitality into the global research and development of cerebrovascular diseases.
On the endless journey of exploring healthcare, the Lattice® Flow Diverter is just the beginning for AccuMedical. With more Chinese enterprises joining in, we have reason to believe that the future healthcare field will be even more exciting, with an increasing number of innovative products bringing more hope and possibilities to human health. Let us look forward to seeing the power of Chinese medical innovation shining brightly on the global stage.